Study to Evaluate the Food Effect of Single-dose Bioavailability of Pracinostat in Healthy Adult Subjects

NCT02058784 | Completed Early Phase 1

• 1 other identifier: MEI-006
• Study Type: interventional
• Target: 28
• Locations: 1 country
• Sites: 1

Brief Summary

Open label study of Pracinostat will be tested to assess the effect of food on the single-dose pharmacokinetics in healthy non-smoking and smoking adult subjects under fasted and fed conditions.

Conditions

Healthy Volunteers; Moderate to Heavy Smokers; Non-smokers

Outcome Measures

Primary Outcomes (1)

• Assess the effect of food on a single-dose PK of pracinostat in nonsmoking healthy adult subjects

  Assess the ratios of least square means of pracinostat plasma PK parameters AUC 0-t, AUC 0-inf and Cmax for pracinostat under fed versus fasted conditions

  3 days

Secondary Outcomes (1)

• Evaluate the safety and tolerability of a single-dose of pracinostat under fasted and fed conditions in healthy nonsmoking and smoking adult subjects

  1 month

Study Arms (2)

Single-dose food effect in nonsmokers

EXPERIMENTAL

Randomized, two-treatment design in nonsmoking healthy subjects. Single-dose pracinostat to be given under fasted and fed conditions followed by PK sampling for up to 48 hour post dose.

Drug: pracinostat

Single-dose food effect in smokers

EXPERIMENTAL

Single-dose parallel treatment design in moderate to heavy smoking healthy subjects. Single-dose pracinostat will be given under fasted conditions followed by PK blood sampling up to 48 hours.

Drug: pracinostat

Interventions

pracinostat DRUG

Single-dose food effect in nonsmokers; Single-dose food effect in smokers

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Healthy, adult, male or female, 18-55 years of age, inclusive, at screening.
• Cohort 1 only: continuous nonsmoker who has not used nicotine-containing products for at least 6 months prior to the first dose and confirmed by urine cotinine test at screening.
• Cohort 2 only: moderate to heavy smokers defined as \> 1 pack of cigarettes per day or \> 39 cigarettes per week for at least 6 months prior to the first dose and confirmed by urine cotinine test at screening.
• Body Mass Index (BMI) ≥ 18.5 and ≤ 32.0 kg/m2 at screening.
• Medically healthy with no clinically significant medical history, physical examination, laboratory profiles, vital signs or ECGs, as deemed by the PI.
• For a female of non-childbearing potential:
• A non vasectomized, male subject must agree to use a condom with spermicide or abstain from sexual intercourse during the study until 90 days beyond the last dose of study medication. (No restrictions are required for a vasectomized male provided his vasectomy has been performed 4 months or more prior to study start. A male who has been vasectomized less than 4 months prior to study start must follow the same restrictions as a non vasectomized male).
• Understands the study procedures in the informed consent form (ICF), and be willing and able to comply with the protocol

You may not qualify if:

• Subject is mentally or legally incapacitated or has significant emotional problems at the time of screening visit or expected during the conduct of the study.
• History or presence of clinically significant medical or psychiatric condition or disease in the opinion of the PI.
• History of any illness that, in the opinion of the PI, might confound the results of the study or poses an additional risk to the subject by their participation in the study.
• History or presence of alcoholism or drug abuse within the past 2 years prior to screening.
• History or presence of hypersensitivity or idiosyncratic reaction to the study medication or related compounds.
• History of prolonged QT syndrome.
• Positive urine drug and alcohol results at screening or check-in.
• Positive results at screening for HIV, HBsAg or HCV.
• Seated blood pressure is less than 90/40 mmHg or greater than 140/90 mmHg at screening.
• Seated heart rate is lower than 40 bpm or higher than 99 bpm at screening.
• QTcF interval, is \>430 msec (males) or \>450 msec (females) or deemed clinically abnormal by the PI at screening or Period 1 check-in
• Unable to refrain from or anticipates the use of:
• Any drug, including prescription and non-prescription medications, herbal remedies, or vitamin supplements beginning approximately 14 days prior to the first dose of study medication and throughout the study.
• Any drugs known to be significant inducers of CYP enzymes, including St. John's Wort, for 28 days prior to the first dose dosing of study medication and throughout the study. Appropriate sources will be consulted by the PI or designee to confirm lack of PK/pharmacodynamics interaction with study medication.
• Have been on a diet incompatible with the on-study diet, in the opinion of the PI, within the 28 days prior to the first dose of study medication(s), and throughout the study.

Sponsors & Collaborators

• Helsinn Healthcare SA: lead
• Celerion: collaborator

Study Sites (1)

Celerion

Tempe, Arizona, 67296, United States

Location

MeSH Terms

Interventions

SB939 compound

Study Officials

• Terry E O'Reilly, MD

  Celerion

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: early phase 1
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: OTHER
• Intervention Model: CROSSOVER
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: February 6, 2014
• First Posted: February 10, 2014
• Study Start: February 1, 2014
• Primary Completion: March 1, 2014
• Study Completion: March 1, 2014
• Last Updated: February 23, 2017

Record last verified: 2017-02

Locations

US (1)